At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 489 enrolled
Drug / intervention
Lurasidone HCldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Placebo-Controlled, CLinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Lurasidone HCl for Schizophrenia. Completed, enrolled 489 participants across 48 sites in 7 countries.
Detailed Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesFrance, India, Malaysia, Romania, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2007
First PostedOct 2007
Primary CompletionOct 2010
TodayJul 2026
First PostedOct 26, 2007
Enrollment StartOct 1, 2007
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 18.7 years ago
Interventions
Lurasidone HCldrug
Once daily